-transparent.png){kind=logo}
Mitoxantrone at a dose of 12 mg/m2 i.v. q 3 weeks failed to produce a response in 28 adequately treated patients with measurable advanced bladder cancer. The side-effects observed in this group of patients with a good performance status were generally mild. On the basis of this negative result the use of mitoxantrone in this disease cannot be recommended.
Related Publications
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
December 1989,
European journal of cancer & clinical oncology,
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
August 1989,
European journal of cancer & clinical oncology,
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
January 1988,
Progress in clinical and biological research,
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
January 1990,
European journal of cancer (Oxford, England : 1990),
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
April 1999,
European urology,
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
January 1995,
British journal of cancer,
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
January 1998,
European urology,
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
January 1984,
Progress in clinical and biological research,
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
August 1988,
European journal of cancer & clinical oncology,
A T van Oosterom, and
S D Fosså, and
J H Mulder, and
A Calciati, and
M de Pauw, and
R Sylvester
January 1995,
European urology,
